Because 13% survival is not enough, PanCAN has set a bold goal: Drive the five-year survival rate to 20% by 2030. We will do this by accelerating research, expanding patient support and championing the thriving field this disease demands.

Researchers hope to improve survival rates through early detection with a blood test that can detect over 50 types of cancer.

Gene that drops early in pancreatic tumors linked to shorter survival at stage II. Findings could guide future treatment decisions.

Enhanced chemosensitivity: Laboratory data suggest PRP makes resistant pancreatic tumor cells more responsive to standard chemotherapies and alters the tumor microenvironment — including reduced fibrosis and dampened TGF-β pathway signaling.

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct. Accounting for more than 90% of all pancreatic cancers, PDAC is extremely difficult to treat and has a very high mortality rate.